PDS Biotech Announces Acceptance Of Abstract On Combination Of PDS0301 With Docetaxel In Metastatic Prostate Cancer For Oral Presentation By The National Cancer Institute At Cytokines 2023
Portfolio Pulse from Benzinga Newsdesk
PDS Biotechnology Corporation (NASDAQ:PDSB) announced that an abstract on interim data from a clinical trial evaluating the combination of PDS0301, an IL-12-based immunocytokine, with the chemotherapy medication docetaxel has been accepted for oral presentation at the 11th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2023). The trial is investigating the safety, immune responses and clinical activity of PDS0301 and docetaxel in metastatic castration-sensitive and castration-resistant prostate cancer patients.
July 17, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PDS Biotech's abstract acceptance for presentation at a major conference could potentially increase visibility and interest in the company's ongoing clinical trial and its product PDS0301.
The acceptance of the abstract for presentation at a major conference increases the visibility of PDS Biotech's ongoing clinical trial and its product PDS0301. This could potentially attract more interest from the scientific community and investors, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100